Thursday, November 22, 2018

Lupin gets EIR from USFDA for its Nagpur facility

USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.




Drug firm Lupin on Monday said it has received an establishment inspection report (EIR) from the US health regulator post the inspection of its Nagpur facility. "The United States Food and Drug Administration (USFDA) conducted a pre approval inspection for its Phenytoin Sodium Extended Release 100 mg capsules," Lupin said in a filing to BSE.
The plant was inspected by USFDA in September 2018, the company added.
USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
GET TWO DAYS FREE TRIAL>>>>COMMODITY TIPS

No comments:

Post a Comment

Suven Life Sciences gains 3% on product patents in Brazil and Eurasia

These two patents are valid through 2023 and 2034 respectively. Suven Life Sciences shares gained 2.7 percent in morning on Thursd...